PMID- 20412816
OWN - NLM
STAT- MEDLINE
DCOM- 20100914
LR  - 20100607
IS  - 1872-9096 (Electronic)
IS  - 0166-3542 (Linking)
VI  - 87
IP  - 1
DP  - 2010 Jul
TI  - Analysis of the epitope and neutralizing capacity of human monoclonal antibodies 
      induced by hepatitis B vaccine.
PG  - 40-9
LID - 10.1016/j.antiviral.2010.04.006 [doi]
AB  - Hepatitis B virus (HBV) is an infectious agent that is a significant worldwide 
      public health issue. However, the mechanism by which vaccination-induced 
      antibodies prevent HBV infection remains unclear. To investigate the mechanism by 
      which antibodies induced by hepatitis B surface Ag (HBsAg)-vaccination prevent 
      HBV infection in humans, we prepared human monoclonal antibodies (mAbs) against 
      HBsAg using a novel cell-microarray system from peripheral blood B-lymphocytes 
      from vaccinated individuals. We then characterized the IgG subclass, L-chain 
      subtype, and V-gene repertoire of the H/L-chain, as well as affinities of each of 
      these mAbs. We also determined the epitopes of the individual mAbs using 
      synthesized peptides, and the HBV-neutralizing activities of mAbs using the 
      hepatocyte cell line HepaRG. Consequently, IgG1 and kappa chain was mainly used 
      as the mAbs for HBsAg. Seventy percent of the mAbs bound to the loop domain of 
      the small-HBsAg and showed greater neutralizing activities. There were no 
      relationships between their affinities and neutralization activities. A 
      combination of mAbs recognizing the first loop domain showed a synergistic effect 
      on HBV-neutralizing activity that surpassed conventional hepatitis B-Ig (HBIG) in 
      the HepaRG cell line assay. These results may contribute to the development of 
      effective mAb treatment against HBV infection replacing conventional HBIG 
      administration.
CI  - 2010 Elsevier B.V. All rights reserved.
FAU - Tajiri, Kazuto
AU  - Tajiri K
AD  - Department of Immunology, University of Toyama, Japan. 
      tajikazu@med-u.toyama.ac.jp <tajikazu@med-u.toyama.ac.jp>
FAU - Ozawa, Tatsuhiko
AU  - Ozawa T
FAU - Jin, Aishun
AU  - Jin A
FAU - Tokimitsu, Yoshiharu
AU  - Tokimitsu Y
FAU - Minemura, Masami
AU  - Minemura M
FAU - Kishi, Hiroyuki
AU  - Kishi H
FAU - Sugiyama, Toshiro
AU  - Sugiyama T
FAU - Muraguchi, Atsushi
AU  - Muraguchi A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100420
PL  - Netherlands
TA  - Antiviral Res
JT  - Antiviral research
JID - 8109699
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Hepatitis B Antibodies)
RN  - 0 (Hepatitis B Surface Antigens)
RN  - 0 (Hepatitis B Vaccines)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulin Variable Region)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal/*immunology
MH  - Antibodies, Neutralizing/*immunology
MH  - Antibody Affinity
MH  - B-Lymphocytes/immunology
MH  - Base Sequence
MH  - Cell Line
MH  - *Epitope Mapping
MH  - Hepatitis B Antibodies/*immunology
MH  - Hepatitis B Surface Antigens/*immunology
MH  - Hepatitis B Vaccines/*immunology
MH  - Hepatitis B virus/*immunology
MH  - Hepatocytes/virology
MH  - Humans
MH  - Immunoglobulin G/immunology
MH  - Immunoglobulin Variable Region/genetics
MH  - Male
MH  - Middle Aged
MH  - Molecular Sequence Data
EDAT- 2010/04/24 06:00
MHDA- 2010/09/15 06:00
CRDT- 2010/04/24 06:00
PHST- 2010/02/22 00:00 [received]
PHST- 2010/03/30 00:00 [revised]
PHST- 2010/04/14 00:00 [accepted]
PHST- 2010/04/24 06:00 [entrez]
PHST- 2010/04/24 06:00 [pubmed]
PHST- 2010/09/15 06:00 [medline]
AID - S0166-3542(10)00576-0 [pii]
AID - 10.1016/j.antiviral.2010.04.006 [doi]
PST - ppublish
SO  - Antiviral Res. 2010 Jul;87(1):40-9. doi: 10.1016/j.antiviral.2010.04.006. Epub 
      2010 Apr 20.